149 related articles for article (PubMed ID: 18519783)
1. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics.
Wang L; Kumar S; Fridley BL; Kalari KR; Moon I; Pelleymounter LL; Hildebrandt MA; Batzler A; Eckloff BW; Wieben ED; Greipp PR
Clin Cancer Res; 2008 Jun; 14(11):3503-13. PubMed ID: 18519783
[TBL] [Abstract][Full Text] [Related]
2. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Lichter DI; Danaee H; Pickard MD; Tayber O; Sintchak M; Shi H; Richardson PG; Cavenagh J; Bladé J; Façon T; Niesvizky R; Alsina M; Dalton W; Sonneveld P; Lonial S; van de Velde H; Ricci D; Esseltine DL; Trepicchio WL; Mulligan G; Anderson KC
Blood; 2012 Nov; 120(23):4513-6. PubMed ID: 23018640
[TBL] [Abstract][Full Text] [Related]
3. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics.
Martin YN; Salavaggione OE; Eckloff BW; Wieben ED; Schaid DJ; Weinshilboum RM
Pharmacogenet Genomics; 2006 Apr; 16(4):265-77. PubMed ID: 16538173
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis and chromosomal localization of the mouse Psmb5 gene coding for the constitutively expressed beta-type proteasome subunit.
Kohda K; Matsuda Y; Ishibashi T; Tanaka K; Kasahara M
Immunogenetics; 1997; 47(1):77-87. PubMed ID: 9382924
[TBL] [Abstract][Full Text] [Related]
5. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies.
Wood TC; Salavagionne OE; Mukherjee B; Wang L; Klumpp AF; Thomae BA; Eckloff BW; Schaid DJ; Wieben ED; Weinshilboum RM
J Biol Chem; 2006 Mar; 281(11):7364-73. PubMed ID: 16407288
[TBL] [Abstract][Full Text] [Related]
6. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
Haertle L; Barrio S; Munawar U; Han S; Zhou X; Simicek M; Vogt C; Truger M; Fernandez RA; Steinhardt M; Weingart J; Snaurova R; Nerreter S; Teufel E; Garitano-Trojaola A; Da Viá M; Ruiz-Heredia Y; Rosenwald A; Bolli N; Hajek R; Raab P; Raab MS; Weinhold N; Haferlach C; Haaf T; Martinez-Lopez J; Einsele H; Rasche L; Kortüm KM
Clin Cancer Res; 2023 Jan; 29(1):279-288. PubMed ID: 36282272
[TBL] [Abstract][Full Text] [Related]
7. Human glucocorticoid receptor alpha gene (NR3C1) pharmacogenomics: gene resequencing and functional genomics.
Niu N; Manickam V; Kalari KR; Moon I; Pelleymounter LL; Eckloff BW; Wieben ED; Schaid DJ; Wang L
J Clin Endocrinol Metab; 2009 Aug; 94(8):3072-84. PubMed ID: 19435830
[TBL] [Abstract][Full Text] [Related]
8. Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics.
Moyer AM; Salavaggione OE; Hebbring SJ; Moon I; Hildebrandt MA; Eckloff BW; Schaid DJ; Wieben ED; Weinshilboum RM
Clin Cancer Res; 2007 Dec; 13(23):7207-16. PubMed ID: 18056202
[TBL] [Abstract][Full Text] [Related]
9. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
10. Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies.
Freimuth RR; Eckloff B; Wieben ED; Weinshilboum RM
Pharmacogenetics; 2001 Dec; 11(9):747-56. PubMed ID: 11740338
[TBL] [Abstract][Full Text] [Related]
11. Human histamine N-methyltransferase pharmacogenetics: gene resequencing, promoter characterization, and functional studies of a common 5'-flanking region single nucleotide polymorphism (SNP).
Wang L; Thomae B; Eckloff B; Wieben E; Weinshilboum R
Biochem Pharmacol; 2002 Aug; 64(4):699-710. PubMed ID: 12167489
[TBL] [Abstract][Full Text] [Related]
12. Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.
Pereira NL; Aksoy P; Moon I; Peng Y; Redfield MM; Burnett JC; Wieben ED; Yee VC; Weinshilboum RM
J Mol Cell Cardiol; 2010 Nov; 49(5):864-74. PubMed ID: 20692264
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.
Gilbert JA; Salavaggione OE; Ji Y; Pelleymounter LL; Eckloff BW; Wieben ED; Ames MM; Weinshilboum RM
Clin Cancer Res; 2006 Mar; 12(6):1794-803. PubMed ID: 16551864
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
[TBL] [Abstract][Full Text] [Related]
15. Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.
Varga G; Mikala G; Kiss KP; Kosóczki É; Szabó E; Meggyesi N; Balassa K; Kövy P; Tegze B; Szombath G; Tordai A; Andrikovics H; Homolya L; Masszi T
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):734-742. PubMed ID: 28733196
[TBL] [Abstract][Full Text] [Related]
16. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
17. Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.
Shi CX; Zhu YX; Bruins LA; Bonolo de Campos C; Stewart W; Braggio E; Stewart AK
Mol Cancer Res; 2020 Oct; 18(10):1453-1464. PubMed ID: 32561655
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
Allmeroth K; Horn M; Kroef V; Miethe S; Müller RU; Denzel MS
Leukemia; 2021 Mar; 35(3):887-892. PubMed ID: 32690882
[No Abstract] [Full Text] [Related]
20. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
